Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tilpisertib Fosmecarbil · GS-5290

Small molecule · developed by GILEAD SCIENCES

Phase 2 Most advanced trial
GILD Developer
1 Registered trials

What is Tilpisertib Fosmecarbil?

Tilpisertib Fosmecarbil is an investigational small-molecule drug studied in Ulcerative Colitis.

At a glance

Also known as
GS-5290
Drug type
Small molecule
Therapy area
Gastroenterology
Developer
GILEAD SCIENCES (GILD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
H1W0G02O9T

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06029972 Phase 2 Ulcerative Colitis Active not recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis

More from GILEAD SCIENCES

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Tilpisertib Fosmecarbil

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.